Articles tagged with Cancer Medication
Researchers have identified potential therapeutic targets for muscle-invasive bladder cancer, including genes and pathways disrupted in the disease. The study also found similarities between subtypes of bladder cancer and those of other cancers, such as breast, head and neck, and lung cancers.
Researchers have identified 32 genes with recurring defects in muscle-invasive bladder cancer, offering a roadmap for targeted treatments. The study also found frequent alterations in chromatin regulation and viral DNA involvement in bladder cancer development.
A study found that patients with ALK+ non-small cell lung cancer can continue treating with crizotinib after receiving targeted radiation therapy to eliminate resistant disease pockets. This approach improves 2-year survival rates compared to those who discontinued the drug earlier.
Researchers have discovered a new combination therapy that leverages existing experimental therapies to speed the fight against cancer. The approach, which combines SMAC Mimetics with live virus therapies, shows a synergistic tumour-killing effect, overcoming limitations of individual agents.
Researchers at the University of Toronto have developed a method to assemble gold nanoparticles using DNA as a vehicle to deliver cancer medications or markers directly into cancerous tumors. The particles can be precisely engineered to target specific tumor types and stages.
Scientists have discovered a critical weakness in the microscopic transport system within cells, which could be targeted for cancer treatment. The study reveals that a narrow seam along microtubules is the weakest point, leading to its dissolution when cracked or split.
A recent study by Loyola Medicine finds that many internists feel ill-equipped to care for adult childhood cancer survivors due to inadequate education and training. The study highlights the need for primary care physicians to have access to survivorship care plans and guidelines.
A landmark study across many cancer types reveals that the universe of cancer mutations is much bigger than previously thought. The team's work expands the list of known genes tied to these cancers by 25 percent.
A new study published in the New England Journal of Medicine finds that idelalisib reduces tumor size by at least half in 57% of patients with indolent non-Hodgkin lymphoma. The drug's side effects are manageable, offering a targeted and less harmful approach to treating cancer.
Scientists at Weill Cornell Medical College have found that a twice-daily pill, idelalisib, can turn deadly blood cancer into a highly treatable disease. The study suggests that patients with CLL may avoid debilitating chemotherapy, leading to significant side effects and death.
The Jackson Laboratory will receive a five-year, $7.5 million grant to develop new mouse models and tumor repository for cancer genomics research. The collaboration with Seoul National University aims to advance individualized cancer diagnosis and treatment.
Researchers identified microRNA-22 as a key player in Ewing's Sarcoma, regulating KDM3A gene expression. Targeting KDM3A with small-molecule inhibitors may provide new therapeutic options for the disease.
A Moffitt Cancer Center study found that consistent HPV vaccine recommendations from family doctors are lacking, contributing to low vaccination rates. The research team recommends more HPV vaccine recommendations by family physicians to increase uptake.
Researchers have found that trastuzumab can improve outcomes for bladder cancer patients with HER2 amplification, a known driver of aggressive tumors. The study identified 15% of MPUC patients had HER2 amplification, leading to faster growth and higher recurrence rates.
Researchers at Columbia University Medical Center found a single mutation in osteoblasts can cause AML in mice and nearly 40% of patients with the disease. The mutation leads to cancer in adjacent bone-marrow stem cells through signaling pathways.
The Damon Runyon-Rachleff Innovation Award funds groundbreaking projects that aim to prevent, diagnose, and treat cancer. This year's recipients are Emily P. Balskus, Arvin C. Dar, Summer L. Gibbs, Xiaolin Nan, Moritz F. Kircher, and Eirini Papapetrou, who will receive $450,000 over three years for their innovative ideas.
A multinational project led by Dr. Tyler Curiel aims to develop an antibody that can block a specific cancer metabolic pathway and reduce its ability to suppress the immune system.
A new analysis reveals steady progress against cancer's burden, despite underestimation due to other disease advancements. Researchers measured years of life lost to cancer and found increased longevity offsetting progress.
Researchers at the University of Leicester successfully used Vemurafenib, a BRAF inhibitor approved for melanoma, to clear malignant cells from a patient's blood and achieve complete clinical recovery. The study demonstrates the potential for repurposing existing cancer treatments for rare types of leukemia.
Researchers have developed a novel DNA-barcoded antibody sensing approach to analyze hundreds of cancer-related protein markers from miniscule patient samples. This technology enables comprehensive analysis of protein expression patterns in single cells, revealing significant differences between tumors and predicting treatment response.
A comprehensive genetic study of multiple myeloma has identified subpopulations of cancer cells with different mutations within the same tumor. This discovery could impact treatment strategies and patient outcomes.
Researchers found that metformin inhibits mTOR pathway, which supports cancer growth, rather than activating AMPK. Metformin may still be useful for cancer treatment, but clinicians should use caution when interpreting data.
A USC study has identified a viral microRNA cluster responsible for causing Kaposi's sarcoma, the most common cancer among HIV-infected people. The cluster targets key cellular pathways associated with cancer development, offering potential targets for new therapeutics.
Researchers at Johns Hopkins Medicine have identified a small molecule compound called BMH-21 that targets and disrupts a key pathway in cancer cells, preventing their growth. By shutting down the RNA Polymerase pathway, BMH-21 prevents mutant cancer genes from communicating with cells and replicating.
A new study suggests that autophagy plays a key role in determining the fate of cancer cells when treated with anti-cancer drugs. Cells with high levels of autophagy were more susceptible to death from certain drugs, while those with low levels of autophagy were more resistant.
Perphenazine, a 50-year-old antipsychotic medication, has been found to actively combat cells of difficult-to-treat acute lymphoblastic leukemia (ALL) by turning on the cancer-suppressing enzyme PP2A.
Researchers have discovered that a cancer drug can protect the insulin-producing cells in the pancreas and prevent the development of type 1 diabetes in mice. The medication works by reducing sterile inflammation and delaying cell destruction. This finding is a step towards developing a preventive treatment for type 1 diabetes.
Researchers at Case Comprehensive Cancer Center have identified a microRNA biomarker, miR-181a, that predicts treatment response in ovarian cancer. Elevated levels of miR-181a are associated with chemotherapy resistance and disease progression.
Research at the University of North Carolina found that patients with higher co-payments were 70% more likely to stop taking their cancer treatment and 42% more likely to skip doses. The cost of many new pharmaceuticals can exceed $100,000 per year.
Researchers found that mutations in phosphatases lead to dysfunction of regulatory proteins that keep the oncogene in check, causing it to stay activated and promote cancer growth. This discovery suggests a new target for drugs to treat head and neck tumors and other cancers.
Researchers at North Carolina State University developed nanoparticles that deliver two different cancer-killing drugs to separate parts of the cell. The technique, tested on laboratory mice, resulted in significant tumor reduction compared to conventional treatments.
Researchers have identified a way to effectively target the beta3-integrin protein, which has been at the center of cancer drug design for 20 years. The new approach shows promise in inhibiting tumor growth and angiogenesis in mice.
Researchers analyzed nearly 20,000 people with severe psychiatric illness, finding that 30% engaged in binge drinking, 75% were regular smokers, and 50% used marijuana regularly. These findings are concerning because individuals with severe mental illness tend to die younger due to health problems caused by chronic substance use.
Researchers have identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets, suggesting that these tumors may be sensitive to MEK inhibitors. The findings could provide a new treatment option for patients with hard-to-treat melanomas.
Researchers at the University of Maryland School of Medicine found that both real and sham acupuncture reduce hot flashes and other symptoms in breast cancer patients taking an aromatase inhibitor. The study suggests that acupuncture may be a reasonable alternative to drug therapy with fewer side effects.
A new Northwestern Medicine study reveals that leading National Cancer Institute-designated comprehensive cancer centers do not consistently identify and inform patients about their fertility risks or refer them to specialists. Fertility navigators are crucial in bridging the gap between oncology and fertility, but only a third of thes...
A new radiotherapy technique uses a computer-controlled table to deliver high doses of radiation to tumors quickly and precisely, while sparing vulnerable organs. Researchers found that this method can substantially reduce the amount of radiation delivered to healthy tissue in patients with various types of cancer.
The Ben & Catherine Ivy Foundation awarded a $3 million grant to TGen, Nemucore Medical Innovations Inc., and Barrow Neurological Institute to develop targeted therapies for glioblastoma. The collaboration aims to create personalized medicine by bridging the blood-brain barrier.
A University of Colorado Cancer Center study found that ALK and ROS1 gene rearrangements, known to drive subsets of lung cancer, are also present in some colorectal cancers. This implies that drugs used to target ALK and ROS1 in lung cancer may have applications in treating a subset of colorectal cancer patients.
Researchers have found that an experimental drug targeting tumor-associated macrophages decreases glioblastoma growth and extends the survival of laboratory mice with the cancer. The treatment increases rates of programmed cell death in both the macrophages and tumor cells, leading to reduced tumor proliferation and increased survival.
A Mayo Clinic study found that endoxifen, an active metabolite of tamoxifen, is safe and shows anti-tumor activity in early-stage trials. The findings suggest a potential new treatment for estrogen-positive breast cancer patients who don't respond to standard hormonal therapies.
Researchers develop individualized systems medicine strategy to select effective cancer therapies for patients, understanding and predicting drug resistance. The approach aids in optimizing patient therapies, with promising results in treating chemoresistant adult acute myeloid leukemia (AML) patients.
A study by Dana-Farber Cancer Institute and Yale University found that moderate daily exercise can decrease joint pain in postmenopausal women taking aromatase inhibitors for breast cancer. After a year, joint pain scores decreased by 20% in the exercise group compared to 3% in the non-exercise group.
Researchers at Fox Chase Cancer Center are enrolling patients in a clinical trial of the promising drug reparixin, which targets tumors' ability to self-renew. The study aims to learn more about the effect of the drug on human breast cancer cells and its mechanisms of action.
A phase II clinical trial at the University of Texas M. D. Anderson Cancer Center showed that a combination of rituximab and pidilizumab sparked complete responses in 19 out of 29 patients with relapsed follicular lymphoma, with a response rate of 66%. The treatment had a mild side effect profile, with no grade 3 or 4 adverse events.
Researchers at Johns Hopkins Medicine found that erlotinib, a drug approved to treat lung cancer, substantially shrunk chordoma tumors in mice. The study offers new hope for chordoma patients who have exhausted traditional treatments and have limited financial incentives for pharmaceutical companies to develop new drugs.
Researchers at Dana-Farber Cancer Institute found a combination chemotherapy and targeted therapy reduced cancer recurrence in women with small, HER2-positive tumors. After 3.6 years, only 0.5% of patients experienced cancer recurrence.
Four University of Houston researchers have been elected National Academy of Inventors Fellows for their groundbreaking work in cancer treatment and materials science. The new fellows include Rathindra Bose, Dmitri Litvinov, Zhifeng Ren, and Venkat Selvamanickam, who collectively hold over 5,600 US patents.
A new study found that Herceptin plus Taxol is highly effective in treating lower-risk breast cancer patients, with a 98.7% success rate of being cancer-free for at least three years. The treatment had minimal side effects, with only 3.2% experiencing severe neuropathy.
Researchers from UCLA's Jonsson Comprehensive Cancer Center found that glioblastoma cells can temporarily eliminate gene mutations when exposed to cancer drugs, becoming drug-resistant. After the drug is removed, the tumor cells reacquire the mutation, repeating this cycle and making treatment more challenging.
Research advances demonstrate progress in cancer fight, but also stress need for increased funding to translate research into effective treatments. The report highlights three areas of progress: genomics, treatment-resistant cancers, and targeted immunotherapy.
Researchers have identified a specific genetic mutation driving Waldenstrom's Macroglobulinemia in up to 30% of patients. A new drug targeting this mutation shows promise in animal studies, offering hope for targeted treatment options.
A new gene sequencing project identifies a family of drugs that enhance oxidative stress to kill rhabdomyosarcoma tumor cells and boost chemotherapy effectiveness. The study offers hope for treating this aggressive childhood cancer, particularly for patients with recurrent disease.
Researchers at Rutgers University have developed a targeted drug delivery system that successfully treats advanced-stage ovarian cancer in mice. The treatment involves using small inhibiting RNA molecules to decrease excess CD44 protein in cancer cells while treating with anti-cancer drug paclitaxel.
Researchers identified CUX1 as a driver of tumour growth in over 3,000 cancer patients worldwide. Inactivating CUX1 leads to increased tumour progression and activation of PIK3IP1, mobilising phosphoinositide 3-kinase (PI3K) for cell growth.
A novel drug regimen featuring bortezomib has been shown to improve outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors. The regimen reduced severe acute GVHD rates and treatment-related mortality, leading to better overall survival and relapse-free survival.
A new study published in Blood journal presents a Swedish cancer drug candidate that inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The substance also kills multiple myeloma cells from cancer patients and overcomes resistance to clinically used drugs.
Researchers discovered that glioblastoma (GBM) tumor cells hide the signaling molecule targeted by therapies, adding complexity to current models of drug resistance. The findings suggest alternative approaches that could improve outcomes for cancer patients and may have significant implications for therapeutic regimens.
Researchers found that brain cancer cells temporarily lose their EGFRvIII gene mutation to evade drugs, then re-amplify it after therapy is stopped. This 'hide-and-seek' mechanism makes targeted therapies less effective, with implications for improving treatment outcomes.
Medical researchers at the University of Alberta found that one chemotherapy drug prevents another from working, making combination therapy ineffective. This discovery will guide oncologists on how to combine or avoid certain drugs, ultimately leading to better treatment options for patients.